Werewolf Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Werewolf Therapeutics has a total shareholder equity of $117.6M and total debt of $39.4M, which brings its debt-to-equity ratio to 33.5%. Its total assets and total liabilities are $177.6M and $60.0M respectively.
Key information
33.5%
Debt to equity ratio
US$39.42m
Debt
| Interest coverage ratio | n/a |
| Cash | US$139.19m |
| Equity | US$117.59m |
| Total liabilities | US$60.01m |
| Total assets | US$177.60m |
Recent financial health updates
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Recent updates
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Financial Position Analysis
Short Term Liabilities: HOWL's short term assets ($142.3M) exceed its short term liabilities ($21.2M).
Long Term Liabilities: HOWL's short term assets ($142.3M) exceed its long term liabilities ($38.8M).
Debt to Equity History and Analysis
Debt Level: HOWL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if HOWL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HOWL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: HOWL has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 18.4% each year.